Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III

被引：0
|
作者：
Hasenburg, A. [1 ]
Harter, P. [2 ]
Park-Simon, T-W. [3 ]
Gropp-Meier, M. [4 ]
Heitz, F. [2 ]
Soergel, P. [5 ]
Ataseven, B. [6 ]
Friedlaender, M. [7 ]
Hilpert, F. [8 ]
Pujade-Lauraine, E. [9 ]
机构：
[1] Univ Ctr Mainz, Dept Gynecol & Obstet, Klin & Poliklin Geburtshilfe & Frauengesundheit, Mainz, Germany
[2] Kliniken Essen Mitte, Gynakol & Gyn Onkol, Essen, Germany
[3] Hannover Med Sch, Klin Frauenheilkunde & Geburtshilfe, Hannover, Germany
[4] Malteserkrankenhaus Bonn, Ravensburg, Germany
[5] Hannover Med Sch, Hannover, Germany
[6] Kliniken Essen Mitte, Klin Senol, Essen, Germany
[7] Prince Wales Hosp, Randwick, NSW, Australia
[8] Univ Klinikum Schleswig Holstein, Klin Gynakol & Geburtshilfe, Kiel, Germany
[9] Univ Paris 05, Paris, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
538
引用
收藏
页码：88 / 89
页数：2
相关论文
共 48 条
  • [31] Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
    Hall, Michael J.
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui, Karen
    Joo, Seongjung
    Yoo, Hyun Kyoo
    Patel, Nikunj
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
    Arnold, D.
    Hall, M. J.
    Golan, T.
    Hammel, P.
    Reni, M.
    Van Cutsem, E.
    Macarulla, T.
    Park, J. O.
    Hochhauser, D.
    Oh, D-Y
    Reinacher-Schick, A.
    Tortora, G.
    Algul, H.
    O'Reilly, E.
    McGuiness, D.
    Cui, K.
    Joo, S.
    Yoo, H. K.
    Patel, N.
    Kindler, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 217 - 217
  • [33] Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.
    Trillsch, Fahian
    Mahner, Sven
    Ataseven, Beyhan
    Asher, Rebecca
    Dubot, Coraline
    Clamp, Andrew R.
    Peson, Richard T.
    Oza, Amit M.
    Amit, Amnon
    Huzarski, Tomasz
    Casado, Antonio
    Scambia, Giovanni
    Friedlander, Michael
    Colombo, Nicoletta
    Fujiwara, Keiichi
    Sonke, Gabe S.
    Denys, Hannelore
    Lowe, Elizabeth S.
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
    Elyashiv, Osnat
    Ledermann, Jonathan
    Parmar, Gita
    Farrelly, Laura
    Counsell, Nicholas
    Feeney, Amanda
    El-Khouly, Fatima
    Macdonald, Ian
    Neto, Andreia
    Arthur-Darkwa, Esther
    Burnett, Eva
    Jayson, Gordon C.
    Mileshkin, Linda
    Gourley, Charlie
    Nicum, Shibani
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 134 - 138
  • [35] Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO 2/ENGOT Ov-21 trial
    Frenel, J-S.
    Kim, J-W.
    Berton-Rigaud, D.
    Asher, R.
    Vidal, L.
    Pautier, P.
    Ledermann, J. A.
    Penson, R. T.
    Oza, A. M.
    Korach, J.
    Huzarski, T.
    Pignata, S.
    Colombo, N.
    Park-Simon, T-W.
    Tamura, K.
    Sonke, G. S.
    Freimund, A.
    Lee, C. K.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S615 - S615
  • [36] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial (vol 18, pg 1274, 2017)
    Pujade-Lauraine, E.
    Ledermann, J. A.
    Selle, F.
    LANCET ONCOLOGY, 2017, 18 (09): : E510 - E510
  • [37] EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS AS MAINTENANCE MONOTHERAPY
    Sackeyfio, A.
    Santi, I
    Friedlander, M.
    VALUE IN HEALTH, 2018, 21 : S73 - S73
  • [38] Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.
    Poveda, Andres
    Lheureux, Stephanie
    Colombo, Nicoletta
    Cibula, David
    Lindemann, Kristina
    Weberpals, Johanne I.
    Bjurberg, Maria
    Oaknin, Ana
    Sikorska, Magdalena
    Gonzalez Martin, Antonio
    Madry, Radoslaw
    Jesus Rubio, Maria
    Ledermann, Jonathan A.
    Davidson, Richard
    Blakeley, Christopher
    Bennett, James
    Brown, Jessica
    Skof, Erik
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).
    Frenel, Jean-Sebastien
    Kim, Jae-Weon
    Berton, Dominique
    Asher, Rebecca
    Vidal, Laura
    Pautier, Patricia
    Ledermann, Jonathan A.
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lowe, Elizabeth S.
    Freimund, Alison E.
    Lee, Chee Khoon
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.
    Poveda, Andres
    Lheureux, Stephanie
    Colombo, Nicoletta
    Cibula, David
    Lindemann, Kristina
    Weberpals, Johanne, I
    Bjurberg, Maria
    Oaknin, Ana
    Sikorska, Magdalena
    Gonzalez Martin, Antonio
    Madry, Radoslaw
    Rubio Perez, Maria Jesus
    Davidson, Richard
    Blakeley, Christopher
    Bennett, James
    Barnicle, Alan
    Skof, Erik
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345